Compare Hilton Hotels Corporation Common Stock (HLT) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Johnson & Johnson — how do they compare? Hilton Hotels Corporation Common Stock trades at $326.94 (market cap $72.76B), while Johnson & Johnson trades at $260.33 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 8.5× Hilton Hotels Corporation Common Stock's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Johnson & Johnson for 129 Days on average.
| HLT | JNJ | |
|---|---|---|
Market Cap | $72.76B | $618.09B |
Volume | 1,148,634 | 6,050,983 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $278.43 |
52-Week Low | $256.96 | $186.00 |
Typical Hold Time | 138 Days | 129 Days |
Enterprise Value | $85.78B | $646.37B |
Dividend Yield | 0.19% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $327.48, up 2.18% today, reflecting strong momentum near its recent highs. The stock shows a bullish technical setup with consistent earnings beats in recent quarters and solid revenue growth, with 2025 revenue reaching $12.04 billion. Analyst sentiment is positive, with a consensus price target of $348.11 and no sell ratings among 49 analysts. Recent news highlights institutional buying and the upcoming Q3 2026 earnings report on October 27, 2026.
The outlook for HLT remains favorable, driven by robust travel demand, global portfolio expansion, and strong operational cash flow. Key risks include high debt levels, with a debt-to-asset ratio rising to 73.88% in 2025, and sensitivity to economic cycles. Upside potential hinges on continued execution and market share gains in high-growth regions like Asia, as noted in recent company reports.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
